Clinical trials in Vandoeuvre Les Nancy – page 7

587 clinical trials in Vandoeuvre Les Nancy, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Vandoeuvre Les Nancy at a glance

587

clinical trials

Research sites2

Quick filters

587 trials in Vandoeuvre Les Nancy

Open in trial search

Non-small cell lung cancer stage IV+2

Recruiting

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Central nervous system lymphoma

Recruiting

Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

Registered drugNo placebo

Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:DB-1303
Sponsor:BioNTech SE

Contact Research Centre

Antibiotic level therapeutic

Recruiting

Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

Registered drugNo placebo

Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amikacin Sulfate
Sponsor:Centre Hospitalier Universitaire De Nimes

Contact Research Centre

Hepatitis alcoholic

Recruiting

Study of N-acetylcysteine and prednisolone combination versus extended prednisolone treatment in patients with severe alcoholic hepatitis

Registered drug

Study of N-acetylcysteine and prednisolone combination versus extended prednisolone treatment in patients with severe alcoholic hepatitis

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Acetylcysteine
Sponsor:Centre Hospitalier Universitaire De Lille

Contact Research Centre

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Everolimus
Sponsor:Pfizer Inc.

Contact Research Centre

Adenocarcinoma pancreas

Recruiting

Study of Gemcitabine with Paclitaxel versus Standard Chemotherapy Combination for Patients with Borderline Resectable Pancreatic Cancer Based on Gene Analysis

Registered drugNo placebo

Study of Gemcitabine with Paclitaxel versus Standard Chemotherapy Combination for Patients with Borderline Resectable Pancreatic Cancer Based on Gene Analysis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Breast cancer metastatic

Recruiting

Study of Trastuzumab Deruxtecan Blood Levels in Normal Weight and Overweight Patients with Metastatic Breast Cancer

Registered drugNo placebo

Study of Trastuzumab Deruxtecan Blood Levels in Normal Weight and Overweight Patients with Metastatic Breast Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan
Sponsor:Oncopole Claudius Regaud

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer

Registered drugNo placebo

Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Glioblastoma

Recruiting

Study of iodofalan (131I) and lomustine combination therapy compared to lomustine alone in patients with first recurrent glioblastoma

Registered drugNo placebo

Study of iodofalan (131I) and lomustine combination therapy compared to lomustine alone in patients with first recurrent glioblastoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lomustine
Sponsor:Telix Pharmaceuticals (Innovations) Pty Limited

Contact Research Centre

Pulmonary arterial hypertension

Recruiting

A study of LTP001 in combination with standard treatment for adults with pulmonary arterial hypertension

Investigational

A study of LTP001 in combination with standard treatment for adults with pulmonary arterial hypertension

Investigational

France

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:LTP001
Sponsor:Novartis Pharma AG

Contact Research Centre

Adenocarcinoma pancreas+2

Recruiting

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Novartis Pharma AG

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Vandoeuvre Les Nancy

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancer types, including head and neck squamous cell carcinoma, multiple myeloma, and prostate cancer. Studies evaluate new therapeutic approaches and diagnostic methods.

Advanced cancer treatments
Therapeutic combinations
Survival outcomes

Several trials investigate novel drug combinations and targeted therapies for improving patient outcomes.

02 Autoimmune Conditions

Comprehensive research into inflammatory bowel diseases, particularly Crohn's disease and ulcerative colitis. Studies explore innovative treatments including microbiota transplantation and new biological therapies.

Disease management
Treatment efficacy
Long-term outcomes

Trials aim to develop more effective maintenance therapies and improve quality of life for patients.

03 Neurological Disorders

Groundbreaking research in multiple sclerosis treatment, including both progressive and relapsing forms. Studies evaluate new therapeutic approaches and disease progression markers.

Disease modification
Treatment safety
Clinical outcomes

Focus on developing innovative treatments for better management of neurological conditions.

Back to France All countries